A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)
Amgen
Amgen
Amgen
Amgen
Amgen
Amgen
Hoffmann-La Roche
Amgen
Amgen
Deciphera Pharmaceuticals, LLC
Amgen
Vitrac Therapeutics, LLC
Allist Pharmaceuticals, Inc.
Ningbo Newbay Technology Development Co., Ltd
Effector Therapeutics
Criterium, Inc.
Amgen
Erasca, Inc.